

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61K 31/415, 9/16, 9/00, 9/50	A1	(11) International Publication Number: WO 94/12180 (43) International Publication Date: 9 June 1994 (09.06.94)
(21) International Application Number: PCT/EP93/03272 (22) International Filing Date: 22 November 1993 (22.11.93) (30) Priority Data: 9224855.8 27 November 1992 (27.11.92) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CHAUHAN, Sushil [GB/GB]; SmithKline Beecham, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB). FRANCE, Gordon [GB/GB]; SmithKline Beecham, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB). BUEHLER, John [US/US]; 1111 Hunt Seat Drive, Lower Gwynedd, PA 19002 (US). (74) Agent: THOMPSON, Clive, B.; Corporate Intellectual Property, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CIMETIDINE GRANULES COATED WITH A PARTIALLY HYDROGENATED VEGETABLE OIL (57) Abstract A pharmaceutical composition is described comprising cimetidine granules coated with a partially hydrogenated vegetable oil.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CIMETIDINE GRANULES COATED WITH A PARTIALLY HYDROGENATED VEGETABLE OIL

5 This invention relates to granules of cimetidine which are useful in the preparation of pharmaceutical compositions having an improved flavour.

Cimetidine is a histamine H₂-antagonist and has been described in UK. Patent Specification 1,397,436. Cimetidine has been shown to be useful in the treatment of duodenal, gastric, recurrent and stomal ulceration, and reflux oesophagitis and in the management of patients who are at high risk from haemorrhage of the upper gastro-
10 intestinal tract.

Cimetidine is known to have a pronounced bitter taste. This is not usually a problem when the dosage form employed is a capsule or a tablet designed to be swallowed, thereafter to disintegrate upon reaching the stomach. However, such dosage forms can be impractical when it is desired to administer a large amount of active
15 ingredient, or to co-administer a relatively bulky second active ingredient such as an antacid or alginate. Moreover many individuals have difficulty in swallowing a solid dosage form.

A conventional approach to administering relatively large amounts of active ingredient is by means of a suspension or a chewable tablet, i.e. a tablet which
20 disintegrates in the mouth upon being chewed.

It will be appreciated that a major requirement of such dosage forms is that they must be palatable, since an unpalatable formulation increases the risk of a patient neglecting to take a medicament. Such non-compliance with the dosing regimen will in turn delay or prevent the patient's recovery from the condition under treatment.

25 A further requirement of such compositions is that once the formulation reaches the stomach, the individual particles should release the active ingredient rapidly and completely in order to ensure that substantially all of the active ingredient is absorbed; that is to say the formulation should be bioavailable.

In the case of cimetidine, because of its bitterness, the provision of such dosage
30 forms represents a considerable problem.

EP-A-257823 describes a stable aqueous suspension of cimetidine wherein at least 90% of the cimetidine is in the polymorphic B form. It is disclosed that the use of polymorph B overcomes the problem of polymorphic interconversion found in the case of polymorph A suspensions of relatively low viscosity which tend to result in lumpy and non
35 homogeneous suspensions.

EP-A-322048 describes a pharmaceutical granule composition comprising cimetidine and an ester of a polyhydroxy compound, in particular a glycerol ester selected from:

- 5
- a) glycerol esters having a hydroxyl value of greater than 120;
 - b) glycerol esters having a hydroxyl value of greater than 60 and having a triglyceride content of less than 30% by weight, and
 - c) glycerol esters having a hydroxyl value of greater than 5 and a melting point of less than 40°C.

It is disclosed that such cimetidine containing granules are useful in the preparation of chewable tablets.

Coated cimetidine granules have now been discovered which have improved flavour. They can be presented in a variety of pharmaceutical forms, e.g., as a chewable
10 tablet, a constitutable powder, or as a sprinkle powder, i.e., a powder that can be sprinkled, for example, onto food before consumption.

In a first aspect the present invention provides a pharmaceutical composition comprising cimetidine granules coated with a partially hydrogenated vegetable oil or a chemical equivalent thereof, in an amount corresponding to at least 20%, suitably from
15 25% to 200%, by weight relative to the cimetidine.

More suitably the partially hydrogenated vegetable oil is present in an amount from 50% to 150%, preferably 75% to 125%, particularly 100% by weight relative to the cimetidine.

The cimetidine can exist in any form, for example, polymorph A, B, C or Z or
20 any mixture thereof, preferably polymorph A.

Partially hydrogenated vegetable oils are derived from natural products and generally comprise a mixture of glycerides of C₁₄₋₂₀ fatty acids, in particular palmitic and stearic acids, said mixture suitably having an iodine value of less than 10 and a melting point greater than 40°C. Preferably said mixture has an iodine value less than 5 and a
25 melting point between 45° and 75°C.

Suitable examples of partially hydrogenated vegetable oils include partially hydrogenated cottonseed oil, soybean oil, corn oil, peanut oil, palm oil, sunflower seed oil or mixtures thereof. Examples of commercially available oils are those sold by Van Den Burgh Foods Company, USA, and include Stearine 07 (partially hydrogenated cottonseed
30 oil), Stearine 17 (partially hydrogenated soybean oil), Stearine 27 (partially hydrogenated palm oil) and K.L.X. (a mixture of partially hydrogenated cottonseed/soybean oil).

Chemical equivalents of partially hydrogenated vegetable oils include synthetically produced glycerides of C₁₄₋₂₀ fatty acids having the same properties as the naturally derived products as hereinbefore described.

35 The coated granules of the present invention can be prepared by adding a partially hydrogenated vegetable oil to cimetidine, warming the mixture until the vegetable oil just melts and mixing for a short period of time until the mixture just granulates.

Alternatively, the granules can be prepared in a spray dryer according to conventional techniques. Preferably the granules are prepared in a hot-melt fluid bed coating process for example as described in J Pharmaceutical Research, Vol 7, No 11, 1990, 1119.

5 In a second aspect the present invention provides a constitutable powder composition comprising coated cimetidine granules as hereinbefore defined and a suspending agent. Such constitutable powders can be mixed with water in order to prepare extemporaneously aqueous cimetidine suspensions.

10 It has been found that such aqueous suspensions have the advantage that cimetidine polymorph A can be used in the coated granules of the present invention without suffering from the problem of polymorphic interconversion.

Examples of suspending agents include xanthan gum, hydroxypropylmethyl-cellulose, methylcellulose, carageenan, sodium carboxymethyl cellulose, and sodium carboxymethyl cellulose/microcrystalline cellulose mixtures, particularly sodium carboxymethyl cellulose/microcrystalline cellulose mixtures. Preferred suspending agents
15 are thixotropic suspending agents such as xanthan gum, carageenan and sodium carboxymethyl cellulose/microcrystalline cellulose mixtures and mixtures thereof and particularly preferred suspending agents are Avicel RC591, Avicel RC581 and Avicel CL611. Avicel is a trademark of FMC Corporation, and RC591, RC581 and CL611 are mixtures of microcrystalline cellulose and sodium carboxymethyl cellulose. The amount
20 of suspending agent present will vary according to the particular suspending agent used and the presence or absence of other ingredients which have an ability to act as a suspending agent or which contribute significantly to the viscosity of the composition. In general, however, the amount of suspending agent will lie in the range 1-50% w/w relative to the coated cimetidine granules. When the suspending agent is xanthan gum, it will
25 usually be present in an amount corresponding to 1-20% w/w relative to the coated cimetidine granules whereas when Avicel is used, the amount typically will lie in the range 5-50% w/w, suitably 10-25% w/w. When carageenan or hydroxypropylmethylcellulose is used, typically this will constitute 5-50% w/w relative to the coated cimetidine granules. Suitably, the suspending agent is a mixture of xanthan gum and hydroxypropylmethyl-
30 cellulose or Avicel in amounts falling within the ranges noted above.

Suitably, the constitutable powder composition also comprises a surfactant. The surfactant improves the wettability of the coated cimetidine granules. Examples of surfactants include co-block polymers such as poloxamer 188 and partial esters of sorbitan and sorbitol and their polyoxyethylene derivatives, e.g. Tween and Span series of
35 surfactants.

A particularly preferred surfactant is Tween 80 which has been found to minimise the degradation of coated cimetidine granules when in aqueous suspension.

The surfactant is generally present in an amount from 0.1 - 10%, suitably 1 - 8%, preferably 2 - 6%, (w/w) relative to the coated cimetidine granules.

The constitutable powder composition can contain ingredients which improve its taste, for example sweeteners, bitter-taste maskers such as sodium chloride and taste-
5 masking flavours such as contramarum, flavour enhancers such as monosodium glutamate, and flavouring agents.

Examples of sweeteners include bulk sweeteners such as sucrose, hydrogenated glucose syrup, the sugar alcohols sorbitol and xylitol, and sweetening agents such as sodium cyclamate, sodium saccharin, aspartame and ammonium glycyrrhizinate.

10 A bulk sweetener will usually be present in an amount corresponding to about 50-1000% relative to the coated cimetidine granules, the amount depending in part upon whether other ingredients are present which have a thickening effect on the composition. For example, when sorbitol is used as the sole bulk sweetener and no thickener is present, typically the dry weight of sorbitol present is in the range 200-800% w/w relative to the
15 coated cimetidine granules.

When hydrogenated glucose syrup (solids content approximately 74%) is used as the sole bulk sweetener, typically it is present in an amount 400-1000% w/w relative to the coated cimetidine granules. It will be appreciated that combinations of bulk sweeteners can be used, for example combinations of sorbitol and hydrogenated glucose syrup, or
20 sucrose and sorbitol.

Other excipients which can be used include humectants such as propylene glycol and glycerol and colourants such as titanium dioxide.

Typically the total quantity of humectant present is in the range 0-150% w/w relative to the coated cimetidine granules. Thus, for example, propylene glycol and
25 glycerol can each be present in an amount approximating to 60% w/w.

The constitutable powder composition can contain preservatives to prevent microbial contamination. Examples of preservatives are the alkylparabens, such as methylparaben, propylparaben and butylparaben.

The constitutable powder composition can be prepared by blending the
30 ingredients together to form a dry powder mix which can be packaged into suitable containers for example glass or plastic bottles. Such bottles are sufficiently large so that in use the requisite amount of water can be added whilst leaving sufficient head space to allow efficient shaking of the contents to aid constitution. If desired the coated cimetidine granules can initially be mixed with the surfactant in the presence of sufficient water or
35 glycerol to aid mixing until the surfactant is uniformly adsorbed onto the cimetidine granules. After drying the mixture can be blended with the remaining ingredients.

In a third aspect the present invention provides a chewable tablet comprising coated cimetidine granules as hereinbefore defined.

Such tablets normally contain at least 75 mg of cimetidine. As a maximum the tablet will not normally contain more than 800 mg of cimetidine. Preferably it contains 100 to 200 mg of cimetidine.

5 The tablets can also contain solid diluents such as sugars and sugar alcohols, for example lactose, xylitol, sorbitol and mannitol. Where desired additional sweeteners can be added, for example ammonium glycyrrhizinate, sodium cyclamate and sodium saccharinate as well as flavours and taste maskers, for example sodium chloride and Contramaram, and tableting starch, which gives the tablets a palatable texture.

10 The tablets can also contain other standard tableting excipients for example a disintegrant such as a cross-linked polymeric disintegrant; particular examples being cross-linked polyvinyl pyrrolidone and cross-linked carboxymethyl celluloses.

The compositions of this invention can optionally contain an antacid. An antacid is a pharmaceutically acceptable basic material of sufficient neutralising capacity to neutralise stomach acid. Examples of antacids are aluminium hydroxide, magnesium
15 hydroxide, magnesium carbonate, calcium carbonate, sodium carbonate or bicarbonate and co-dried gels for example aluminium hydroxide-magnesium carbonate co-dried gel. Suitable antacids also include those disclosed in US Patent 5169640 and European Patent 294933. Preferably the amount of antacid is such that a unit dose contains 10-30 milliequivalents.

20 The compositions of this invention can optionally contain an alginate including alginic acid.

The purpose of the alginate is to form a raft of mucilage which floats on the contents of the stomach thereby preventing gastro-oesophageal reflux (GORD) or reducing its symptoms. Usually a carbonate salt such as potassium bicarbonate or sodium
25 bicarbonate is added. Reaction of the carbonate with the acidic gastric juices generates carbon dioxide which aerates the alginate raft, reducing its density and thereby enabling it more easily to float on the stomach contents.

In order to avoid too great an increase in the viscosity in the case of a suspension, a low viscosity grade of alginate is used. Low viscosity grades of alginate suitable for use
30 in the compositions of the present invention will generally have a viscosity of 4-10 mPa.s in 1% aqueous solution at 20°C. Alginates are polymers composed of mannuronic and guluronic acid monomer units. The ratio of mannuronic to guluronic acids determines the raft-forming properties of the alginate and, in general, alginates having a high guluronic:mannuronic ratio (e.g. 70% guluronic acid) form the strongest rafts. Alginates
35 containing such high levels of guluronic acid are preferably used in the compositions of the present invention, and one such alginate is Protanal LFR 5/60.

If desired, the present compositions can contain further therapeutic agents, for example, a suitable chewable tablet comprises coated cimetidine granules as herein defined, an antacid, an alginate and simethicone.

The preferred size for the coated cimetidine granules is dependent upon their use.

- 5 For sprinkle powders and constitutable powders, generally the coated granules have an apparent diameter of less than 250 μm , preferably less than 180 μm . For chewable tablets the granules preferably pass through a 1 mm sieve but are retained by a 0.2 mm sieve.

The present invention is illustrated by the following Examples.

10 **Example 1**

Cimetidine - partially hydrogenated cotton seed oil granules.

Granules containing cimetidine (50%) and partially hydrogenated cotton seed oil (stearine 07) (50%) (w/w) are prepared by spraying molten coating material onto a fluidised bed of cimetidine granules.

15

Example 2

Cimetidine - partially hydrogenated soybean oil granules.

In a similar manner to Example 1 granules are obtained containing cimetidine (50%), and partially hydrogenated soybean oil (stearine 17) (50%) (w/w).

20

Example 3

Cimetidine Constitutable Powder

Ingredients	%w/w dry powder mix	g per 100 ml after constitution
Coated cimetidine granules (Ex. 1)	19.56	8.0
Xanthan Gum	0.98	0.4
Hydroxypropylmethylcellulose	7.82	3.2
Tween 80	0.98	0.4
Aspartame	0.98	0.4
Colloidal Silicon Dioxide	1.22	0.5
Sorbitol	61.12	25.0
Sodium Carbonate	3.67	1.5
Flavours	3.67	1.5
Total	100.00	40.9

- The coated cimetidine granules are blended with the remaining ingredients to form a constitutable dry powder mix which is packed into glass or plastic bottles each to contain 81 g of dry powder mix. Each bottle is sufficiently large so that in use the requisite amount of water can be added to the container to produce a final volume of 200 ml, whilst
- 5 leaving sufficient head space in the bottle to allow efficient shaking of the contents to aid constitution. When constituted the suspension contains 200 mg cimetidine per 5 ml.

Example 4

Cimetidine 100 mg Chewable Tablet

Ingredients	mg/tablet
Coated Cimetidine Granules (Example 1)	200.0
Direct Compression Grade Sorbitol	790.0
Direct Compression Grade Lactoses:	
Crystalline	500.0
Spray dried	500.0
Croscarmellose Sodium Type A	60.0
Sodium Saccharin (Dried Fine Powder)	2.0
Aspartame	2.0
Flavourings	16.0
Magnesium Stearate	45.0
	<hr/>
Total	2,115.0

10

The coated cimetidine granules are blended with the remaining ingredients and the resulting mixture is compressed to form tablets.

Example 5**Cimetidine 200 mg Chewable Tablet**

Ingredients	mg/tablet
Coated Cimetidine Granules (Example 1)	400.0
Direct Compression Grade Sorbitol	790.0
Direct Compression Grade Lactoses:	
Crystalline	450.0
Spray dried	450.0
Croscarmellose Sodium Type A	60.0
Sodium Saccharin (Dried Fine Powder)	10.0
Aspartame	1.0
Flavourings	17.5
Magnesium Stearate	45.0
	<hr/>
Total	2,223.5

5 The coated cimetidine granules are blended with the remaining ingredients and the resulting mixture is compressed to form tablets.

Example 6**Cimetidine 200 mg/Alginate Chewable Tablet**

Ingredients	mg/tablet
Coated Cimetidine Granules (Example 2)	400
Alginic acid	500
Sodium Bicarbonate	170
Sorbitol	680
Pregelatinised Starch	30
Croscarmellose Sodium Type A	60
Lactose	330
Aspartame	5
Sodium Saccharin	5
Magnesium Stearate	35
Flavours	50
<hr/>	
Total	2265

- The coated cimetidine granules are blended with the remaining ingredients and the resulting mixture is compressed to form tablets.
- 5

Example 7**Cimetidine 200 mg/Alginate/Antacid/Simethicone Chewable Tablet**

Ingredients	mg/tablet
Coated Cimetidine Granules (Example 1)	400
Aluminium Hydroxide Dried Gel	225
Magnesium Hydroxide	175
Alginic Acid	300
Simethicone	30
Sorbitol (Direct Compression Grade)	900
Lactose (Direct Compression Grade)	300
Pregelatinised Starch	30
Croscarmellose Sodium Type A	60
Aspartame	5
Sodium Saccharin	5
Flavours	40
Magnesium Stearate	30
	<hr/>
Total	2500

The coated cimetidine granules are blended with the remaining ingredients and the
5 resulting mixture is compressed to form tablets.

Claims

1. A pharmaceutical composition comprising cimetidine granules coated with a partially hydrogenated vegetable oil or a chemical equivalent thereof, in an amount
5 corresponding to at least 20% by weight relative to the cimetidine.
2. A composition according to claim 1 wherein the partially hydrogenated vegetable oil is present in an amount from 50% to 150%, preferably 75% to 125% by weight relative to the cimetidine.
10
3. A composition according to claim 1 or 2 wherein the oil is partially hydrogenated cotton seed oil or partially hydrogenated soybean oil or a mixture thereof.
4. A pharmaceutical constitutable powder composition comprising coated
15 cimetidine granules as defined in any one of claims 1 to 3 and a suspending agent.
5. A composition according to claim 4 further comprising a surfactant.
6. A composition according to claim 5 wherein the surfactant is Tween 80.
20
7. A chewable tablet comprising coated cimetidine granules as defined in any one of claims 1 to 3.
8. A pharmaceutical composition according to any one of claims 1 to 7
25 further comprising an antacid.
9. A pharmaceutical composition according to any one of claims 1 to 8 further comprising an alginate.
- 30 10. A pharmaceutical composition according to any one of claims 1 to 9 further comprising simethicone.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/03272

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K31/415 A61K9/16 A61K9/00 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 322 048 (SMITH KLINE DAUELSBERG) 28 June 1989 cited in the application see page 2, line 55 - page 3, line 2 see page 3, line 19 - line 27 see page 3, line 58 - page 4, line 4 see page 4, line 12 - line 15 see page 4, line 19 see page 4, line 33 - line 37 see table 1 --- -/--	1-5,7,8

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

3 February 1994

Date of mailing of the international search report

15.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/EP 93/03272

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0322048	28-06-89	AU-B- 605671	17-01-91
		AU-A- 2915789	19-07-89
		DE-A- 3872199	23-07-92
		WO-A- 8905640	29-06-89
		JP-T- 2502729	30-08-90
		US-A- 5057319	15-10-91

WO-A-9221328	10-12-92	AU-A- 2146792	08-01-93

WO-A-9204893	02-04-92	AU-A- 8546591	15-04-92
		EP-A- 0548238	30-06-93

EP-A-0290229	09-11-88	AU-B- 602582	18-10-90
		AU-A- 1714088	06-12-88
		AU-B- 602583	18-10-90
		AU-A- 1714188	06-12-88
		CA-A- 1304685	07-07-92
		DE-A- 3863963	05-09-91
		DE-A- 3868986	16-04-92
		EP-A- 0294933	14-12-88
		WO-A- 8808703	17-11-88
		WO-A- 8808704	17-11-88
		GB-A- 2204489	16-11-88
		JP-T- 1503385	16-11-89
		JP-T- 2500747	15-03-90
		US-A- 5188839	23-02-93
		US-A- 5169640	08-12-92
		CA-A- 1304686	07-07-92

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/03272

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,92 21328 (AFFINITY BIOTECH INC.) 10 December 1992 see page 3, line 4 - line 18 see page 5, line 33 - line 35 see page 6, line 34 - page 7, line 5 see page 9, line 12 - line 16 see page 9, line 30 - line 37 see example 4 ---	1,2,4,5, 7
A	WO,A,92 04893 (SMITH-KLINE BEECHAM CORPORATION) 2 April 1992 see page 2, line 18 - line 28 see page 3, line 10 - line 14 see page 4, line 5 - line 25 ---	6
A	EP,A,0 290 229 (SMITH KLINE & FRENCH LABORATORIES) 9 November 1988 see claim 1 see page 3, line 36 - line 46 -----	9